Sociedad Americana de Hirudoterapia

Macin family of antimicrobial proteins combines antimicrobial and nerve repair activities

Biochemistry article published in Journal of Biological Chemistry (2012)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Research reportFarmacología salivalResistencia antimicrobianaJung S, Sönnichsen FD, Hung CW et al. · The Journal of biological chemistry, 2012

Abstract

The tertiary structures of theromacin and neuromacin confirmed the macin protein family as a self-contained family of antimicrobial proteins within the superfamily of scorpion toxin-like proteins. The macins, which also comprise hydramacin-1, are antimicrobially active against Gram-positive and Gram-negative bacteria. Despite high sequence identity, the three proteins showed distinct differences with respect to their biological activity. Neuromacin exhibited a significantly stronger capacity to permeabilize the cytoplasmic membrane of Bacillus megaterium than theromacin and hydramacin-1. Accordingly, it is the only macin that displays pore-forming activity and that was potently active against Staphylococcus aureus. Moreover, neuromacin and hydramacin-1 led to an aggregation of bacterial cells that was not observed with theromacin. Analysis of the molecular surface properties of macins allowed confirmation of the barnacle model as the mechanistic model for the aggregation effect. Besides being antimicrobially active, neuromacin and theromacin, in contrast to hydramacin-1, were able to enhance the repair of leech nerves ex vivo. Notably, all three macins enhanced the viability of murine neuroblastoma cells, extending their functional characteristics. As neuromacin appears to be both a functional and structural chimera of hydramacin-1 and theromacin, the putative structural correlate responsible for the nerve repair capacity in leech was located to a cluster of six amino acid residues using the sequence similarity of surface-exposed regions.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsAntimicrobial Cationic PeptidesBase SequenceCloning, MolecularDisulfidesHumansLeechesMagnetic Resonance SpectroscopyMolecular Sequence DataNeuronsProtein Conformation

Resumen

Tertiary structures of theromacin and neuromacin reveal that leech-derived macin antimicrobial peptides also enhance leech nerve repair and promote murine neuroblastoma viability, expanding their therapeutic profile beyond microbicidal activity.

Por qué esto importa para la hirudoterapia

Este estudio caracterizó las actividades biológicas de las proteínas antimicrobianas de la familia macin, confirmando las macinas como una familia distinta dentro de la superfamilia tipo toxina de escorpión, con estructuras terciarias reportadas para theromacin y neuromacin. Las tres proteínas (theromacin, neuromacin, hydramacin-1) mostraron perfiles antimicrobianos distintos contra bacterias Gram-positivas y Gram-negativas, con neuromacin mostrando la mayor actividad de permeabilización de membrana y formación de poros contra Staphylococcus aureus. Notablemente, neuromacin y theromacin mejoraron la reparación nerviosa de la sanguijuela ex vivo, mientras que las tres macinas mejoraron la viabilidad de células de neuroblastoma murino. Para ASH, esto es relevante ya que revela actividades duales antimicrobianas y de reparación nerviosa en proteínas macin asociadas con sanguijuelas. Sin embargo, el estudio es preclínico (ex vivo e in vitro), involucra células y tejidos no humanos, e incluye hydramacin-1 de Hydra; no hay datos terapéuticos o clínicos relevantes para la hirudoterapia.

Citación

Macin family of antimicrobial proteins combines antimicrobial and nerve repair activities.

Jung S, Sönnichsen FD, Hung CW et al. · The Journal of biological chemistry, 2012

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.